$ News

Viking Therapeutics Stock Gets RS Rating Upgrade

Rice Hall James Loads Up on BIRK With 466,000 Shares Bought

Rice Hall James Buys QuidelOrtho Stock

Rice Hall James Buys Stride Stock

How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

Amicus Therapeutics: Q4 Earnings Snapshot

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate

TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

Amicus Therapeutics Presents New Data From Clinical And Real-World Studies Of Galafold In Fabry Disease And POMBILITI + OPFOLDA In Late-Onset Pompe Disease At 22nd Annual WORLDSymposium 2026

Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments

Top 3 Health Care Stocks That May Implode In Q1

The Right Play On BioMarin Pharmaceuticals

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

Jefferies Downgrades Amicus Therapeutics to Hold, Lowers Price Target to $14.5

How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know